Suspension of trading

Income Statement SpringWorks Therapeutics, Inc.

Stocks

SWTX

US85205L1070

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2025-06-30 EDT			5-day change	1st Jan Change
46.99 ^USD	+0.02%		-.--%	-

12-15	Immunome jumps after promising results for its desmoid tumor treatment
12-01	Tyra Bioscience Appoints Bhavesh Ashar as Chief Operating Officer	MT

2e882d.5a6tFWJxxqMZke-j_eEDH3PbZn3D29M5XM-hl1E6ULk.pvzvVyYV95NG4rnVk9JGKTSKA02Lsr9jNI7UwhV3Ad2Ew_hZDQny_HrhhA

Published financial data: SPRINGWORKS THERAPEUTICS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
Revenues	35M	-	-	5.45M	172M
Other Revenues, Total	-	-	-	-	19.55M
Total Revenues	35M	-	-	5.45M	192M
Cost of Goods Sold, Total	-	-	-	422K	12.55M
Gross Profit	35M	-	-	5.02M	179M
Selling General & Admin Expenses, Total	29.46M	71.79M	135M	198M	257M
R&D Expenses	51.86M	102M	146M	150M	201M
Other Operating Expenses, Total	81.32M	173M	281M	348M	457M
Operating Income	-46.32M	-173M	-281M	-343M	-278M
Interest And Investment Income	1.33M	698K	6.28M	22.95M	26M
Net Interest Expenses	1.33M	698K	6.28M	22.95M	26M
Income (Loss) On Equity Invest.	-605K	-988K	-2.89M	-5.04M	-6M
Other Non Operating Income (Expenses)	25K	-152K	-138K	-	-
EBT, Excl. Unusual Items	-45.57M	-174M	-277M	-325M	-258M
EBT, Incl. Unusual Items	-45.57M	-174M	-277M	-325M	-258M
Earnings From Continuing Operations	-45.57M	-174M	-277M	-325M	-258M
Net Income to Company	-45.57M	-174M	-277M	-325M	-258M
Net Income - (IS)	-45.57M	-174M	-277M	-325M	-258M
Preferred Dividend and Other Adjustments	-	-	-	-	-
Net Income to Common Incl Extra Items	-45.57M	-174M	-277M	-325M	-258M
Net Income to Common Excl. Extra Items	-45.57M	-174M	-277M	-325M	-258M
Per Share Items
Net EPS - Basic	-1.05	-3.59	-5.21	-5.15	-3.48
Basic EPS - Continuing Operations	-1.05	-3.59	-5.21	-5.15	-3.48
Basic Weighted Average Shares Outstanding	43.3M	48.5M	53.29M	63.12M	74.13M
Net EPS - Diluted	-1.05	-3.59	-5.21	-5.15	-3.48
Diluted EPS - Continuing Operations	-1.05	-3.59	-5.21	-5.15	-3.48
Diluted Weighted Average Shares Outstanding	43.3M	48.5M	53.29M	63.12M	74.13M
Normalized Basic EPS	-0.66	-2.24	-3.25	-3.22	-2.18
Normalized Diluted EPS	-0.66	-2.24	-3.25	-3.22	-2.18
Supplemental Items
EBITDA	-45.98M	-173M	-280M	-341M	-275M
EBITA	-46.32M	-173M	-281M	-343M	-278M
EBIT	-46.32M	-173M	-281M	-343M	-278M
EBITDAR	-44.44M	-171M	-278M	-339M	-272M
Total Revenues (As Reported)	-	-	-	5.45M	192M
Normalized Net Income	-28.48M	-109M	-173M	-203M	-161M
Supplemental Operating Expense Items
General and Administrative Expenses	29.46M	71.79M	135M	198M	-
Research And Development Expense From Footnotes	51.86M	102M	146M	150M	201M
Net Rental Expense, Total	1.54M	1.54M	1.47M	2.52M	2.85M
Stock-Based Comp., R&D Exp. (Total)	3.06M	14.66M	29.37M	34.4M	38.78M
Stock-Based Comp., G&A Exp. (Total)	6.98M	23.78M	43.59M	60.14M	-
Stock-Based Comp., SG&A Exp. (Total)	-	-	-	-	70.36M
Total Stock-Based Compensation	10.03M	38.44M	72.96M	94.53M	109M

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
Assets
Cash And Equivalents	147M	104M	67.49M	176M	69.75M
Short Term Investments	361M	270M	525M	303M	238M
Total Cash And Short Term Investments	508M	374M	592M	479M	308M
Accounts Receivable, Total	-	-	-	5.93M	46.24M
Total Receivables	-	-	-	5.93M	46.24M
Inventory	-	-	-	3.1M	10.21M
Prepaid Expenses	4.91M	9.41M	7.55M	12.68M	16.03M
Total Current Assets	513M	383M	600M	501M	380M
Gross Property Plant And Equipment	3.55M	5.22M	19.51M	26.74M	32.05M
Accumulated Depreciation	-529K	-1.02M	-1.24M	-2.66M	-5.39M
Net Property Plant And Equipment	3.02M	4.2M	18.27M	24.09M	26.66M
Long-term Investments	57.21M	62.11M	8.99M	185M	158M
Other Intangibles, Total	-	-	-	11.2M	15.56M
Deferred Charges Long-Term	-	-	-	-	-
Other Long-Term Assets, Total	2.57M	3.27M	3.23M	4.25M	6.47M
Total Assets	576M	452M	630M	726M	587M
Liabilities
Accounts Payable, Total	1.35M	3.43M	8.01M	7.4M	12.25M
Accrued Expenses, Total	14.88M	25.38M	39.24M	65.57M	86.01M
Current Portion of Leases	1.38M	1.16M	483K	1.06M	1.73M
Unearned Revenue Current, Total	-	-	3.31M	4.14M	-
Other Current Liabilities	-	-	-	-	-
Total Current Liabilities	17.61M	29.97M	51.05M	78.17M	99.99M
Long-Term Leases	1.36M	129K	4.77M	6M	6.18M
Unearned Revenue Non Current	-	-	16.23M	15.4M	-
Other Non Current Liabilities	164K	-	-	-	-
Total Liabilities	19.13M	30.1M	72.05M	99.57M	106M
Preferred Stock Convertible	-	-	-	-	-
Total Preferred Equity	-	-	-	-	-
Common Stock, Total	5K	5K	6K	7K	7K
Additional Paid In Capital	676M	715M	1.13B	1.52B	1.65B
Retained Earnings	-119M	-293M	-570M	-895M	-1.15B
Treasury Stock	-	-	-1.34M	-4.14M	-12.58M
Comprehensive Income and Other	41K	-312K	-767K	1.19M	304K
Total Common Equity	557M	422M	558M	626M	481M
Total Equity	557M	422M	558M	626M	481M
Total Liabilities And Equity	576M	452M	630M	726M	587M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	48.29M	48.87M	62.28M	73.68M	74.92M
ECS Total Common Shares Outstanding	48.13M	48.78M	62.2M	73.38M	74.39M
Book Value / Share	11.57	8.66	8.97	8.53	6.47
Tangible Book Value	557M	422M	558M	615M	466M
Tangible Book Value Per Share	11.57	8.66	8.97	8.38	6.26
Total Debt	2.73M	1.29M	5.25M	7.06M	7.91M
Net Debt	-559M	-431M	-592M	-656M	-454M
Debt Equivalent Oper. Leases	12.28M	12.33M	11.74M	20.15M	22.78M
Equity Method Investments, Total	3.87M	2.88M	4.19M	1.96M	4.19M
Account Code - Inventory Valuation	3	3	3	3	5
Machinery, Total	254K	517K	805K	3.26M	5.93M
Full Time Employees	78	176	227	305	368

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
Net Income	-45.57M	-174M	-277M	-325M	-258M
Depreciation & Amortization - CF	349K	490K	765K	1.67M	2.87M
Amortization of Goodwill and Intangible Assets - (CF)	-	-	-	-	600K
Depreciation & Amortization, Total	349K	490K	765K	1.67M	3.47M
(Income) Loss On Equity Investments - (CF)	605K	988K	2.89M	5.04M	6M
Stock-Based Compensation (CF)	10.03M	38.44M	72.96M	94.53M	109M
Other Operating Activities, Total	1.05M	993K	1.13M	1.65M	1.78M
Change In Accounts Receivable	-	-	-	-5.93M	-40.31M
Change In Inventories	-	-	-	-3.1M	-7.11M
Change In Accounts Payable	-1.3M	2.07M	4.17M	-196K	4.6M
Change in Unearned Revenues	-	-	19.55M	-	-1.76M
Change in Other Net Operating Assets	2.65M	3.04M	14.39M	8.65M	6.72M
Cash from Operations	-32.19M	-128M	-162M	-223M	-176M
Capital Expenditure	-642K	-2.02M	-10.2M	-7.38M	-4.45M
Sale (Purchase) of Intangible assets	-	-	-	-	-16.25M
Investment in Marketable and Equity Securities, Total	-418M	85.61M	-205M	42.14M	85.25M
Cash from Investing	-419M	83.59M	-216M	34.75M	64.54M
Issuance of Common Stock	270M	1.16M	342M	299M	13.2M
Repurchase of Common Stock	-	-	-1.34M	-2.8M	-8.44M
Issuance of Preferred Stock	-	-	-	-	-
Cash from Financing	270M	1.16M	341M	297M	4.76M
Net Change in Cash	-181M	-43.13M	-36.46M	109M	-106M
Supplemental Items
Levered Free Cash Flow	-16.15M	-63.42M	-88.27M	-113M	-112M
Unlevered Free Cash Flow	-16.15M	-63.42M	-88.27M	-113M	-112M
Change In Net Working Capital	-3.06M	-8.08M	-23.62M	-12.38M	29.62M

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
Profitability
Return on Assets	-6.36	-21.08	-32.4	-31.62	-26.48
Return on Total Capital	-6.57	-22.05	-35.54	-35.83	-30.98
Return On Equity %	-10.37	-35.51	-56.58	-54.9	-46.62
Return on Common Equity	-10.37	-35.51	-56.58	-54.9	-46.62
Margin Analysis
Gross Profit Margin %	100	-	-	92.25	93.45
SG&A Margin	84.19	-	-	3.63K	133.96
EBITDA Margin %	-131.36	-	-	-6.27K	-143.36
EBITA Margin %	-132.35	-	-	-6.3K	-144.86
EBIT Margin %	-132.35	-	-	-6.3K	-145.17
Income From Continuing Operations Margin %	-130.21	-	-	-5.97K	-134.73
Net Income Margin %	-130.21	-	-	-5.97K	-134.73
Net Avail. For Common Margin %	-130.21	-	-	-5.97K	-134.73
Normalized Net Income Margin	-81.38	-	-	-3.73K	-84.21
Levered Free Cash Flow Margin	-46.15	-	-	-2.08K	-58.22
Unlevered Free Cash Flow Margin	-46.15	-	-	-2.08K	-58.22
Asset Turnover
Asset Turnover	0.08	-	-	0.01	0.29
Fixed Assets Turnover	18.35	-	-	0.26	7.55
Receivables Turnover (Average Receivables)	-	-	-	-	6.6
Inventory Turnover (Average Inventory)	-	-	-	-	1.89
Short Term Liquidity
Current Ratio	29.15	12.78	11.75	6.41	3.81
Quick Ratio	28.87	12.46	11.6	6.21	3.54
Operating Cash Flow to Current Liabilities	-1.83	-4.27	-3.16	-2.85	-1.76
Days Sales Outstanding (Average Receivables)	-	-	-	-	55.49
Days Outstanding Inventory (Average Inventory)	-	-	-	-	194.15
Average Days Payable Outstanding	-	-	-	-	182.86
Cash Conversion Cycle (Average Days)	-	-	-	-	66.79
Long Term Solvency
Total Debt/Equity	0.49	0.31	0.94	1.13	1.64
Total Debt / Total Capital	0.49	0.3	0.93	1.11	1.62
LT Debt/Equity	0.24	0.03	0.85	0.96	1.28
Long-Term Debt / Total Capital	0.24	0.03	0.85	0.95	1.26
Total Liabilities / Total Assets	3.32	6.65	11.43	13.72	18.08
Total Debt / EBITDA	-0.06	-0.01	-0.02	-0.02	-0.03
Net Debt / EBITDA	12.58	2.52	2.13	1.93	1.67
Total Debt / (EBITDA - Capex)	-0.06	-0.01	-0.02	-0.02	-0.03
Net Debt / (EBITDA - Capex)	12.4	2.49	2.05	1.89	1.64
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-	-	-	-	3.42K
Gross Profit, 1 Yr. Growth %	-	-	-	-	3.46K
EBITDA, 1 Yr. Growth %	-22.14	276.24	61.82	21.95	-19.54
EBITA, 1 Yr. Growth %	-21.8	274.47	61.8	22.21	-19.09
EBIT, 1 Yr. Growth %	-21.8	274.47	61.8	22.21	-18.92
Earnings From Cont. Operations, 1 Yr. Growth %	-21.84	281.6	59.52	17.19	-20.6
Net Income, 1 Yr. Growth %	-21.84	281.6	59.52	17.19	-20.6
Normalized Net Income, 1 Yr. Growth %	-21.84	281.6	59.52	17.19	-20.6
Diluted EPS Before Extra, 1 Yr. Growth %	-72.37	240.7	45.17	-1.07	-32.39
Accounts Receivable, 1 Yr. Growth %	-	-	-	-	679.73
Inventory, 1 Yr. Growth %	-	-	-	-	229.1
Net Property, Plant and Equip., 1 Yr. Growth %	279.75	39.02	335.29	31.85	10.68
Total Assets, 1 Yr. Growth %	72.08	-21.47	39.28	15.16	-19.08
Tangible Book Value, 1 Yr. Growth %	72.96	-24.17	32.15	10.18	-24.3
Common Equity, 1 Yr. Growth %	72.96	-24.17	32.15	12.19	-23.17
Cash From Operations, 1 Yr. Growth %	-32.15	297.24	26.34	37.9	-21.18
Capital Expenditures, 1 Yr. Growth %	-4.18	214.02	405.75	-27.57	-39.73
Levered Free Cash Flow, 1 Yr. Growth %	-43.18	292.67	39.17	28.23	-1.45
Unlevered Free Cash Flow, 1 Yr. Growth %	-43.18	292.67	39.17	28.23	-1.45
Compound Annual Growth Rate Over Two Years
EBITDA, 2 Yr. CAGR %	57.75	71.16	146.74	40.48	-0.94
EBITA, 2 Yr. CAGR %	58.28	71.12	146.15	40.62	-0.56
EBIT, 2 Yr. CAGR %	58.28	71.12	146.15	40.62	-0.45
Earnings From Cont. Operations, 2 Yr. CAGR %	59.95	72.71	146.72	36.73	-3.54
Net Income, 2 Yr. CAGR %	59.95	72.71	146.72	36.73	-3.54
Normalized Net Income, 2 Yr. CAGR %	59.95	72.71	146.72	36.73	-3.54
Diluted EPS Before Extra, 2 Yr. CAGR %	-85.81	-2.98	122.4	19.84	-18.22
Net Property, Plant and Equip., 2 Yr. CAGR %	208.6	129.77	145.99	139.56	20.8
Total Assets, 2 Yr. CAGR %	245.07	16.25	4.59	26.65	-3.47
Tangible Book Value, 2 Yr. CAGR %	410.41	14.52	0.1	20.67	-8.67
Common Equity, 2 Yr. CAGR %	410.41	14.52	0.1	21.76	-7.16
Cash From Operations, 2 Yr. CAGR %	50.75	64.17	124.03	31.99	4.25
Capital Expenditures, 2 Yr. CAGR %	48.02	73.46	298.52	91.39	-33.93
Levered Free Cash Flow, 2 Yr. CAGR %	35.08	49.37	133.77	33.59	12.41
Unlevered Free Cash Flow, 2 Yr. CAGR %	35.08	49.37	133.77	33.59	12.41
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	-	-	-	-46.21	-
Gross Profit, 3 Yr. CAGR %	-	-	-	-47.64	-
EBITDA, 3 Yr. CAGR %	48.74	110.77	67.99	95.09	16.66
EBITA, 3 Yr. CAGR %	49.08	110.9	67.96	94.91	16.96
EBIT, 3 Yr. CAGR %	49.08	110.9	67.96	94.91	17.04
Earnings From Cont. Operations, 3 Yr. CAGR %	48.5	113.73	68.19	92.5	14.07
Net Income, 3 Yr. CAGR %	48.5	113.73	68.19	92.5	14.07
Normalized Net Income, 3 Yr. CAGR %	48.5	113.73	68.19	92.5	14.07
Diluted EPS Before Extra, 3 Yr. CAGR %	-	-59.05	10.97	69.77	-0.98
Net Property, Plant and Equip., 3 Yr. CAGR %	319.14	136.57	184.3	99.82	85.2
Total Assets, 3 Yr. CAGR %	279.02	110.68	23.47	8	9.08
Tangible Book Value, 3 Yr. CAGR %	393.35	170.32	20.12	3.35	3.3
Common Equity, 3 Yr. CAGR %	393.35	170.32	20.12	3.98	4.43
Cash From Operations, 3 Yr. CAGR %	68.6	108.22	50.45	90.57	11.15
Capital Expenditures, 3 Yr. CAGR %	69.43	90.2	147.81	125.74	30.21
Levered Free Cash Flow, 3 Yr. CAGR %	-	92.78	45.89	91.36	20.71
Unlevered Free Cash Flow, 3 Yr. CAGR %	-	92.78	45.89	91.36	20.71
Compound Annual Growth Rate Over Five Years
EBITDA, 5 Yr. CAGR %	-	-	82.12	79.2	35.99
EBITA, 5 Yr. CAGR %	-	-	82.2	79.34	36.19
EBIT, 5 Yr. CAGR %	-	-	82.2	79.34	36.25
Earnings From Cont. Operations, 5 Yr. CAGR %	-	-	81.94	78.75	34.66
Net Income, 5 Yr. CAGR %	-	-	81.94	78.75	34.66
Normalized Net Income, 5 Yr. CAGR %	-	-	81.94	78.75	34.66
Diluted EPS Before Extra, 5 Yr. CAGR %	-	-	-	-37.08	-1.78
Net Property, Plant and Equip., 5 Yr. CAGR %	-	-	238.68	137.76	101.88
Total Assets, 5 Yr. CAGR %	-	-	126.46	71.87	11.89
Tangible Book Value, 5 Yr. CAGR %	-	-	160.66	95.78	7.65
Common Equity, 5 Yr. CAGR %	-	-	160.66	96.49	8.36
Cash From Operations, 5 Yr. CAGR %	-	-	88.9	73.51	29.92
Capital Expenditures, 5 Yr. CAGR %	-	-	138.55	90.68	46.04
Levered Free Cash Flow, 5 Yr. CAGR %	-	-	-	66.48	31.44
Unlevered Free Cash Flow, 5 Yr. CAGR %	-	-	-	66.48	31.44